Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Islets of Langerhans Stories

2008-12-11 11:30:00

MINNEAPOLIS and ST. PAUL, Minn., Dec. 11 /PRNewswire/ -- The University of Minnesota has received a $40 million pledge for diabetes research from the Richard M. Schulze Family Foundation. Goals for the funding, to be paid over five years, are to capitalize on the University's strength in diabetes research and to accelerate the timeline to translate it into a viable cure for people with type 1 diabetes. The gift is the second largest in the history of the University and the second...

2008-11-20 20:06:56

Doctors have tricked mouse immune systems into thinking cells from a donor pancreas are theirs, bringing hope to diabetes patients, U.S. researchers said. The new technique, to fight type 1 diabetes, eliminated the need for drugs that inhibit immune-system activity in diabetic mice that had insulin-producing islet cell transplantation, Northwestern University Feinberg School of Medicine researchers said. Immunosuppressive drugs prevent bodies from rejecting the islet cells, but they're toxic...

2008-11-10 18:00:00

SAN DIEGO, Nov. 10, 2008 (GLOBE NEWSWIRE) -- MicroIslet Inc. (OTCBB:MIIS) (http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, today announced that it filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code. The company plans to continue operating the business without interruption as management focuses on developing and executing on a corporate restructuring plan. "During the...

2008-10-30 09:00:11

Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes. BHT-3021 is an antigen-specific immunotherapeutic DNA vaccine designed to reverse the underlying autoimmune...

2008-10-28 09:00:07

Geron Corporation (Nasdaq:GERN) today announced the publication of data showing the successful engraftment of human embryonic stem cell (hESC)-derived pancreatic islet-like clusters (ILCs) in diabetic mice. After transplantation, the ILCs continued to express important pancreatic islet proteins, responded to high levels of glucose in the blood, and extended the survival of recipient animals. Pancreatic islet cells normally secrete insulin in response to high levels of glucose in the...

2008-10-24 15:00:09

BOTHELL, Wash., Oct. 24 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (BULLETIN BOARD: BLFS) , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that MicroIslet Inc. (BULLETIN BOARD: MIIS) , a biotechnology company engaged in developing and commercializing cellular therapies for patients with diabetes, has adopted HypoThermosol for preserving, transporting, and storing pancreatic source...

2008-10-21 09:00:12

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell(R), LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes. "Obtaining approval to begin our clinical trial is a major milestone for the company and also makes it easier for LCT to obtain approvals in other...

2008-10-14 09:00:11

DiaKine Therapeutics, developers of drugs designed to cause diabetes to go into remission, announced today that a Phase 2 Clinical Trial with the Company's lead drug candidate, Lisofylline (LSF), is underway. Use of LSF may improve the long-term success of transplanting islets (the insulin-producing cells of the pancreas) into people with type 1 diabetes. The trial is part of the Clinical Islet Transplantation (CIT) Consortium created by National Institutes of Health. The protocol,...

2008-09-29 18:00:00

FRIENDLY bacteria in the gut may protect against insulin- dependent diabetes, a study suggests. In tests on mice, the bugs appeared to stop the rogue immune response that triggers the disease. Type 1 diabetes is caused by an autoimmune response which destroys insulin-producing islet cells in the pancreas. Scientists in America studied genetically engineered diabetic mice whose immune systems lacked a key protein that allowed them to respond to bacteria. When they were given back a...

2008-09-22 21:00:12

In tests on mice, the bugs appeared to stop the rogue immune response that triggers the disease.Type 1 diabetes is caused by an autoimmune response which destroys insulin-producing islet cells in the pancreas.About 300,000 people in the UK suffer from the disease. The condition often develops in childhood and has to be controlled with daily insulin jabs.The US study, of mice, showed that harmless bacteria could prevent type 1 diabetes. It also demonstrated the role played by an immune system...